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Introduction
Sudden and intrusive thoughts and insupportable 
behaviors routinely happen for everybody. Similar to 
any category, higher levels of these desires and thoughts 
can exceed the standard level and disrupt a person’s 
ordinary life. Obsessive-compulsive disorder (OCD) is 
a neurological disorder in which a person experiences 
repetitive thought (called “obsessions”) or feels compelled 
to replicate such routines (called “compulsions”) to the 
point of anxiety or impairment of general functioning. 
Over time, the person cannot manage his or her thoughts 
or actions.1 Hand washing, counting items, and testing to 
see if a door is locked are all common compulsions. These 
tasks occur to the point that they adversely influence 
the person’s ordinary activities, often taking more than 
an hour a day. Most adults are aware that their actions 
are illogical. Tics, paranoia, and a higher risk of suicide 
are also linked to the disease. If an individual shows 
compulsion and obsession, the person will be diagnosed 
with OCD2 (Figure 1).
The prevalence of OCD is at a high level and affects 
approximately 3% of the population.3,4 On the other 
hand, its economic and socio-individual health burdens 
are significant for the individual and consequently 
for the society. An abnormal fear of contamination, 
uncontrollable anxiety about it, as well as excessive and 
frequent washing are the apparent symptoms of OCD.5 
Moreover, persistence and resistance to strange behaviors 
are typical features of a patient with OCD. The sufferer’s 
gap between mental purpose and behavior is termed 
“egodystonia” and is one of the thousands of unsolved 
issues still unknown to the neuroscientist. The field 
in the cognitive neuroscience of mental health would 
undoubtedly progress if any of these problems and puzzles 
can be solved (OCD). The age at which OCD manifests 
itself is bimodal, peaking in early adolescence and late 
childhood or again in 20-29 years.6
While treatment significantly impacts symptom 
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progression, most patients have continuous symptoms, 
with up to one-fourth having a waning and waxing pattern.7 
The living standards of patients with OCD are declining, 
as are those with schizophrenia.8 Because the symptoms of 
OCD start from internal factors and thoughts, the patient 
is reluctant to retell or share his or her problem out of 
shame or denial. As a result, it takes almost eight years from 
the onset of OCD symptoms to the first pharmacological 
therapy.9 It was previously assumed that OCD did not 
respond to any treatment such as medication, systematic 
desensitization, or traditional dynamic psychotherapy.10 
Meyer indicated that symptoms of patients with OCD 
increased as they were subjected to feared stimuli while 
refraining from undertaking compulsions, and it was the 
first significant nonpharmacological advance in OCD 
therapy.11 The effectiveness of this method, known as 
exposure and response prevention (ERP), was promising 
in hospitalized patients or outpatients. However, the 
significant improvement in patients did not last for more 
than two years after treatment.12 Although OCD has long 
been recognized, successful therapeutic strategies have 
only been discovered in the past few decades. The first 
randomized clinical trial of clomipramine in OCD took 
place in 1980.13 With the advent of selective serotonin 
reuptake inhibitors (SSRIs) and ERP therapy, we have 
undergone a time of rapid progress in the pharmacological 
and psychotherapeutic treatment of OCD.
Along with these biomedical breakthroughs, 
advancements in neuroimaging have elucidated the neural 
architecture that underpins OCD, opening the way for 
cutting-edge circuit-based neuro therapies. While these 
advancements have considerably changed the treatment 
of patients with OCD, many still suffer from significant 
residual symptoms. Current cognitive and therapeutic 
approaches to OCD mainly focus on neuroscience and 
biological abnormalities. In this review article, considering 
these approaches, modern treatment methods and their 
effectiveness in improving the symptoms of patients with 
OCD will be discussed.
OCD Symptoms
In general, OCD, as mentioned earlier, occurs in the 
form of compulsive and obsessive behaviors that are 
performed to reduce the anxiety caused by the influx of 
intrusive and unconscious thoughts by the individual.14 
The most typical symptoms of OCD include excessive 
worry about contamination and consequent constant 
washing. In addition, worrying about harm to self and 
others and as a result repeated checking is another sign 
of OCD. Moreover, other subtypes have been identified, 
including a set of symptoms related to symmetry, ritual 
order, and cluster focused on hoarding through factor 
analysis. However, OCDs are diverse and include musical, 
physical, religious, and sexual subtypes.14 The variety of 
OCD symptoms is almost constant over time and place, so 
that over the years and in different cultures and places, the 
symptoms are almost the same. In addition, the incidence 
and type of symptoms do not vary between adults and 
children, although the symptoms may change over time 
in each person.15
Nevertheless, the symptoms are different in patients 
with and without tic.16 This difference can be justified 
based on psychological differences. While most 
patients understand that their symptoms are excessive, 
their intuition varies, and others are labeled as having 
low insight. Frontal lesions can be linked to a lack of 
understanding of OCD signs.17 Patients with obsessional 
slowness may have a different form of OCD with further 
neurological disability. Understanding these differences 
and variations in people with OCD, especially from the 
physiological and neuroscientific aspects, can lead to 
more accurate diagnoses and better treatment options17,18 
(Table 1).
The Main Ways for OCD Diagnosis
General medical disorders or the effects of a substance 
on the body that affects a person’s behavior cannot be 
identified as an OCD by the criteria set by the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-IV), 
which sets the standard criteria for identifying mental 
illness.21 Various neurological lesions in the cortico-
striatal-thalamic-cortical pathways have been linked to 
obsessive-compulsive (OC) symptoms. They can occur 
following the application of dopamine agonists (such 
as methylphenidate or cocaine) or after streptococcal 
infection22,23 (presumably on an autoimmune basis).24 
OCD signs must be compounded by severe anxiety 
to be clinically meaningful. Subclinical OCD signs 
are typical and may appear at any time during a child’s 
growth. Patients with OCD, on the other hand, may suffer 
significant consequences, including a lower standard of 
life.25,26 One of the most common mistakes in recognizing 
OCD is compulsion and obsession as inflexible 
personality traits in OCD classification. Although it is 
difficult to distinguish between axis I disorders, including 
Figure 1. OCD Cycle.
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the personality traits of a person with OCD, and axis II 
disorders, such as OC personality disorder, there is a 
difference between OCD and perfectionist behaviors 
or extreme conscientiousness. Some symptoms such as 
obsession and compulsion are inseparable symptoms of 
other disorders such as autism, forehead lip lesions, and 
Tourette’s syndrome.
In contrast, some disorders are easily distinguished 
from OCD, which can be referred to as patients with body 
dysmorphic27 disorder who are concerned about imagined 
ugliness and hypochondriasis (extreme concern about 
getting various diseases). These disorders fall into the 
spectrum of OCD while they are different from OCD.27 
Epidemiology of OCD
In the United States, OCD affects 2%-3% of people at some 
point in their lives. OCD manifests itself in a bimodal 
fashion, with onsets in infancy and late adolescence/early 
adulthood. Just 15% of cases begin after 35, and two-
thirds begin before the age of 25. A third of all cases begin 
in childhood or early adolescence. Men have an early 
onset and a more malignant prognosis compared with 
women. These symptoms will last for years, and affected 
individuals often suffer in silence until the symptoms 
appear. The disorder progresses in a chronic waxing 
and fading pattern, with 15% of patients experiencing 
regression and 5% experiencing episodes of inter-episode 
rehabilitation.28
Etiology of OCD
It is unclear if different forms of OC symptoms have 
a hereditary or environmental cause. For example, 
whether hoarding is etiologically linked to prototypic OC 
symptoms like washing, testing, and obsessing is unclear.29 
It is still unclear if specific OC signs are etiologically 
linked to an overall propensity to suffer emotional 
distress. In any case, the etiology of OCD is classified into 
the following items:
(A) Familial/Genetic factors: Monozygotic twins have 
higher concordance frequencies than dizygotic twins, 
according to twin investigations. The incidence of OCD is 
higher if one of the first relatives is infected with OCD or 
Tourette’s syndrome. In addition, if a family member has 
Tourette syndrome, they are more likely to develop both 
OCD and Tourette syndrome. Therefore, it is thought 
that in these families, OCD and Tourette syndrome are 
different expressions of the same genetic defect in the 
family that is inherited.
(B) Behavioral factors: Obsessions are the product of 
combining mental stimulation with anxiety-provoking 
emotions in a two-stage classical instrumental 
conditioning model of OCD. Compulsions are neutral 
habits that have been linked to reduced fear and thereby 
strengthened.30
(C) Neurobiological factors: Hyperactivity in frontal-
subcortical thalamic pathways is implicated in the 
pathogenesis of OCD, according to data from imaging, 
pharmacological, and behavioral research (Figure 2).31 
Based on this hypothesis, hyperactivity in these pathways 
causes excessive activity in the frontal-subcortical 
networks, resulting in the behavioral dysfunction seen in 
OCD. Increased perfusion and metabolism in the orbital 
frontal cortex, anterior cingulated gyrus, and head of the 
caudate nucleus have been found in patients with active 
OCD according to several pieces of functional imaging 
studies such as functional magnetic resonance imaging 
(fMRI), Single-photon emission computed tomography 
(SPECT), and positron emission tomography (PET).32
A Glance at Neuroimaging Findings in OCD
Since the 1980s, neuroimaging tests have shown substantial 
variations between healthy controls and patients with 
OCD. The cortico-striatal-thalamo-cortical (CSTC) 
paradigm for the neurobiology of OCD was proposed 
Table 1. Symptoms of OCD
Symptoms Explanation Themes Examples Ref.
Obsession
Thoughts, impulses, or images that are 
distracting and cause anxiety or fear, are 
repetitive, constant, and unwelcome.
• Contamination of soil phobia
• Doubting yourself and finding it 
impossible to accept confusion
• Desiring things to be 
symmetrical and tidy
• Thoughts of losing control and 
hurting yourself or others
• Unwelcome thoughts
• Fear of being infected 
by touching items that 
others have touched
• When things are not 
in place or facing 




Compulsions are repeated activities that you 
feel compelled to do in people with OCD. These 
habits or behavioral actions are intended to 
alleviate fear caused by the obsessions or avoid 
anything unpleasant. Compulsions, on the other 
hand, provide little gratification and can only 
provide brief relief from anxiety.




• Hand-washing until 
the skin is red and 
irritated
• Checking doors 
repeatedly to make 
sure they are locked
20
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after initial imaging studies revealed hyperactivity in 
the prefrontal cortex (primarily the orbitofrontal cortex 
[OFC]), anterior cingulate cortex (ACC), and caudate 
nucleus. Nevertheless, research from the last two decades 
shows that widespread associative networks, including 
parts of the parietal cortex, limbic areas (including the 
amygdala), and the cerebellum, are involved. There are 
numerous studies about functional imaging studies 
such as fMRI, PET, SPECT, and functional near-infrared 
spectroscopy (fNIRS).33
 PET scans calculate glucose metabolic concentrations 
in different parts of the brain and are linked to brain 
function. PET experiments have demonstrated 
hypermetabolism of OCD in various regions of the 
PFC since the early 1980s. In a study by Le Jeune and 
colleagues, 10 patients were selected randomly and treated 
with high-frequency bilateral deep brain stimulation  of 
the subthalamic nucleus (STN DBS). By PET analysis, the 
level of glucose metabolism in the right frontal middle 
gyrus was compared to the healthy group. All 10 patients 
had median Yale-Brown Obsessive-Compulsive Scale 
(Y-BOCS) ratings of 31 (minimum: 18, maximum: 36) 
for “Off-Stimulation” and 19 (minimum: 0, maximum: 
30) for “On-Stimulation” (P=0.05). Compared to the 
stable control group, patients with OCD displayed hyper 
metabolism in the right frontal middle and superior 
gyri, right parietal lobe, postcentral gyrus, and bilateral 
putamen in off-stimulation status. On-Stimulation 
conditions showed a substantial reduction in cortical 
metabolism in the left cingulate gyrus and left frontal 
medial gyrus compared to Off-Stimulation conditions. 
Furthermore, Y-BOCS score improvements during on-
stimulation conditions were positively associated with 
PET signal changes at the OFC-medial prefrontal cortex 
border and between PET signal changes and Y-BOCS 
score changes in on-stimulation status. According to 
this report, the therapeutic role of STN DBS seems to be 
linked to a reduction in prefrontal cortex metabolism, 
according to this report.34
Blood flow, receptor availability, and drug absorption 
are all investigated in SPECT experiments. Reduced 
uptake in the OFC, ACC, and posterior cingulate cortex 
(PCC), temporal, parietal, and occipital cortices and 
improved uptake in the cerebellum have been observed 
in SPECT findings in patients with OCD.35 In one study, 
resting regional cerebral blood flow (rCBF) was examined 
in 26 untreated patients with OCD and 22 healthy control 
people. In the right lateral OFC and the left dorsal ACC, 
patients with OCD have slightly lower ECD absorption 
than control subjects (Z-scores greater than 3.29, 
P<0.001).36
In another study, single photon emission computed 
tomography with hexamethyl propylenamine oxime 
(HMPAO SPECT) was used to test rCBF in 16 drug-free 
Brazilian patients with OCD and 17 healthy subjects. The 
right superior and inferior frontal cortex and the right 
and left thalamus were shown to have substantially higher 
rCBF after covariance analysis.37 Overall, in PET and 
SPECT studies, positively correlations have been between 
OFC, DLPFC, lateral and medial temporal cortex, and 
inferior parietal lobule uptakes concerning Y-BOCS 
symptom intensity. However, negative correlations 
have been found with posterior cingulate uptake and 
serotonin transporter activity in hypothalamic and 
thalamic regions. In previous neuroimaging studies, 
5-HT1A, 5-HT2A, D2, and GABA were compared between 
504 patients with anxiety disorder and 593 controls 
via PET or SPECT methods. Significant decreases of 
striatal D2 receptors in OCD (-18%), cingulate 5-HT1A 
receptors (-18%), striatal D2 receptors (-21%) and frontal 
(-14%), temporal (-14%), occipital (-13%) and cingulate 
GABAA receptors (-15%) were reported in patients 
including those with OCD. Moreover, 5-HT and GABA 
can inhibit DAergic neurotransmission, so the reduction 
in 5-HT1A and GABAA can lead to high-level activity of 
the mesolimbic DAergic system. Based on the results, it 
can be acknowledged that DA, 5-HT, and GABA have 
considerable role in anxiety- and compulsion-related 
disorders such as OCD.38
Despite the vast amount of PET and SPECT trials 
published, they all had flaws, such as limited sample 
sizes and inconsistencies in inclusion/exclusion criteria 
for comorbidity, symptom dimensions, and drug status. 
Furthermore, the SPECT experiments used different 
reference regions for estimation, using the cerebellum and 
some using the occipital cortex. Because of these limits, it 
is impossible to extrapolate the results. Many trials have 
looked at pre- and post-treatment shifts, making them 
a valuable method for understanding the neurobiology 
Figure 2. Risk Factors Involved in OCD Incidence.
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of OCD and defining treatment modulation areas. 
FMRI is focused on the measurement of improvements 
in activity and connectivity in various brain areas as a 
function of blood oxygen level dependency. Increased 
functional interaction between the caudate, putamen, 
and OFC and the ACC and para-hippocampal regions 
has been discovered in resting-state fMRI studies. 
Functional integration was compared in a recent meta-
analysis of 18 whole-brain resting-state fMRI trials 
with 572 healthy controls and 541 patients. In OCD, 
researchers discovered reduced connectivity between 
the frontoparietal and salience networks, and between 
the salience, frontoparietal, and default mode networks, 
as well as general dysconnectivity (no apparent increase/
decrease in connectivity) within the default mode, and 
frontoparietal and salience networks.39
FNIRS is a modern, compact, and simple-to-use optical 
imaging modality. It tests oxygenated and deoxygenated 
hemoglobin levels in brain regions to assess brain 
function and is established based on the concept of 
neurovascular coupling. There are two publications based 
on fNIRS among 12 and 20 OCD patients. In one study, 
20 patients with OCD and 20 controls were selected. The 
verbal fluency task consisted of a 30-second pre-task, 
three repetitions of a 20-second verbal fluency task (total 
60 seconds), and a 70-second post-task cycle to evoke 
near-infrared spectroscopic activation. In 14 channels 
spread around the left and right dorsolateral prefrontal 
cortex and frontopolar regions, Z-scores for differences 
in oxygenated hemoglobin concentration were matched 
between patients with OCD and controls. The OCD 
group had significantly lower oxygenated hemoglobin 
concentrations in the right dorsolateral prefrontal cortex 
than the controls. However, the differences were not 
statistically meaningful after several associations were 
corrected. For the patients with OCD, the mean ± SD 
Y-BOCS score was 19.6±8.2, and the mean ± SD MOCI 
(Maudsley Obsessive Compulsive Inventory) score was 
15.5±5.8, while the mean ± SD MOCI score for control 
subjects was 4.3±3.5. There were significant differences 
in the mean MOCI score (t=−7.39, df=38, P< 0.001) and 
verbal fluency scores (t=3.892, df=38, P< 0.001) between 
the two groups. Their founding support of this hypothesis 
that the dorsolateral prefrontal cortex has an essential role 
in OCD pathophysiology.40 
In another study, neurobiological function in 12 
patients with OCD and 12 healthy subjects were analyzed 
by fNIRS. During the execution of a Stroop color-word 
task, the relative concentrations of oxyhemoglobin 
(oxy-Hb) were determined with prefrontal probes per 
0.1 s utilizing 24-channel NIRS. The OCD group’s oxy-
Hb changes in the prefrontal cortex were substantially 
lower than the control group, especially in the left lateral 
prefrontal cortex. These findings show that, as assessed 
by NIRS, patients with OCD have decreased prefrontal 
hemodynamic responses.41 According to these two 
studies, patients with OCD, compared to healthy subjects, 
have lower activation in the DLPFC during the verbal 
fluency test and in the left lateral PFC during the Stroop 
task. There are some mega-analytical studies enhancing 
neuroimaging and genetics by meta-analysis that gathered 
data from 16 countries to produce neuroimaging meta-
analyses of nearly 2000 patients from all age ranges, which 
leads to growing our understanding of the neurobiology 
of OCD and its progression over time. These massive 
multicentric studies help overcome the limitations of 
current neuroimaging studies, such as limited sample 
sizes and discrepancies in inclusion/exclusion criteria for 
comorbidity, heterogeneous symptom dimensions, and 
drug status, and enable data comparison.42
Role of Neurochemistry in OCD Development
Considering the established efficacy of serotonin (5-HT) 
reuptake inhibitors, a disruption in serotonergic function 
is considered a primary factor or OCD in recent years.43 
SSRI and clomipramine are some of these inhibitors. 
Neuroimaging experiments examining the density of 
5-HT receptor and transporter utilizing SPECT and PET 
have shown mixed findings. However, they do vindicate 
localized 5-HT anomalies in OCD. In remarkably reduced 
availability of 5-HT transporter in the midbrain and 
thalamus, enhanced availability of 5-HT2A receptor in the 
caudate, and reduced availability of 5-HT2A receptor in 
the prefrontal regions are among them.44 Lower synaptic 
serotonin inside the CSTC circuit involved in OCD is 
thought to be the cause of these results (Figure 3).
Despite the mixed results of these trials and the 
reality that approximately half of the patients with OCD 
treated with an SSRI may not improve, neurotransmitter 
mechanisms other than 5-HT are likely to play a part in 
the OCD pathophysiology.45 Single-photon absorption 
and PET in patients with OCD showed increased 
binding of striatal dopamine transporter density and 
decreased striatal D2/D3 and D1 receptors, indicating 
dopaminergic hyperactivity in this area. As a result, meta-
analyses support the use of antipsychotic drugs as SSRI 
augmentation therapies for OCD, especially the high-
affinity D2 receptor antagonist risperidone. Antipsychotic 
augmentation, on the other hand, works on around 
1/3 of patients with treatment-resistant OCD,44 leaving 
physicians looking for other options.46,47
A function for impaired glutamatergic 
neurotransmission in the pathophysiology of OCD is 
approved by many pieces of evidence.48 By magnetic 
resonance spectroscopy, the accumulation of glutamate 
and its related glutamine metabolite seems to be 
normalized by paroxetine treatment in the caudal nucleus 
of children with OCD during preliminary research.48 
However, recent attempts to reproduce these results have 
overwhelmingly failed. Numerous genes involved in 
Ansari Asl et al
Int Clin Neurosci J. Vol 8, No 3, Summer 2021112 journals.sbmu.ac.ir/Neurosciencehttp
glutamate expression and metabolism, have been linked 
to OCD, prompting the development of transgenic animal 
models of the disorder. Several minor preclinical studies 
have looked at glutamate modulating interventions such 
as memantine, N-acetylcysteine, and riluzole as possible 
SSRI augmentation therapies for OCD. At least in a subset 
of patients with OCD, this shows positive outcomes.49 In 
a limited placebo-controlled crossover study, ketamine 
decreased OCD symptoms after a single intravenous 
injection. However, there is little gain in an open-label 
trial for patients who are more treatment-resistant and 
show severe symptoms of OCD. Overall, further research 
is required to decide if glutamatergic drugs should be 
used to treat OCD.  If glutamic drugs are helpful, it should 
be considered in which group of patients it will be most 
effective.50
Any disruption in the function of the GABA in OCD 
is very important. In patients with OCD, however, 
anomalies in prefrontal inhibitory neurotransmission 
have been discovered, which are thought to be caused 
by low GABAergic activation and low medial prefrontal 
and orbitofrontal cortical GABA levels. Furthermore, an 
abrupt rise in GABA levels in the medial prefrontal cortex 
following ketamine infusion was linked to a dramatic 
decrease in OCD symptoms. These results highlight the 
need for further research into the abnormalities of the 
GABAergic role in OCD.44,51
 The results indicate that a variety of neurochemical 
anomalies could cause OCD. Overactive CSTC circuits, 
as shown by glutamatergic hyperactivity and striatal 
dopaminergic neurons, seem to be at the core of OCD.52 
The cause of this hyperactive condition is unknown; 
however, it may be caused by primary defects in the gene 
involved in glutamate metabolism found in CSTC brain 
regions, or it may be secondary to decreased midbrain 
and prefrontal serotonergic function.53 Via activation of 
5-HT1A receptors, serotonergic projections from the raphe 
nuclei suppress dopaminergic activity in the striatum and 
thalamic activity, while stimulatory 5-HT2A autoreceptors 
on prefrontal GABA interneurons inhibit striatal 
glutamatergic activity.54,55 As a result, SSRIs can help 
alleviate symptoms of OCD via moderating glutamatergic 
hyperactivity and striatal dopaminergic neurons, through 
increased serotonergic inhibition (Figure 3). Reduction in 
the level of prefrontal GABAergic inhibition can enhance 
striatal activation in addition to serotonergic deficits, 
either directly or indirectly through projections to the 
OFC. Although this paradigm is simplistic, it serves as a 
starting point for more research into the pathophysiology 
of OCD and the advancement of new therapeutic 
methods.51
OCD neurobiology is linked to the ACC. Few 
trials, however, have looked directly at functional and 
neurochemical anomalies in the rostral subdivision of 
the ACC (rACC) in OCD patients. In a study by Brennan 
et al, the role and neurochemistry of the rACC in people 
with OCD and people without OCD using fMRI during 
an emotional counting Stroop task and single-voxel 
J-resolved proton magnetic resonance spectroscopy 
(1H-MRS) in the rACC was compared. Linear regression 
was used to investigate inter-group variations in rACC 
activation and glutamine/glutamate ratio (Gln/Glu), Glu, 
Figure 3. Inhibitory interactions and normal excitatory leading to cortico-striatal-thalamo-cortical (CSTC) circuitry are seen in uncomplicated 
manner. Midbrain raphe nuclei and mPFC interneurons both show decreased serotonergic and GABAergic inhibitory tone in the hyper 
activation of CSTC circuit involved in OCD, resulting in striatal dopaminergic and glutamatergic hyperactivity driving unrestrained CSTC 
activity. Neurosurgical interventions that change the hyperactive CSTC circuitry, have been shown to help people with serious, treatment-
resistant OCD. Subcaudate tractotomy, anterior capsulotomy, and anterior cingulotomy are surgical lesions that may be done with an 
open or gamma knife approach. Deep brain stimulation is done only posterior to the capsulotomy lesion target, in the ventral striatum and 
ventral capsule.
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and Gln levels and correlations between rACC activation, 
Gln/Glu, Glu, Gln, behavioral, and clinical measures. 
However, there was no difference in Gln/Glu, Glu, or Gln 
in the rACC between classes, and there was no connection 
between reduced rACC deactivation and Gln/Glu, Glu, or 
Gln in the OCD community. These results support rACC 
dysfunction as a cause of OCD, but they contradict an 
underlying connection to irregular rACC glutamatergic 
neurotransmission.56
Although much progress has been made in 
understanding the social, neurological, and neurochemical 
aspects of OCD individually, their interplay, especially 
during psychotherapy, remains a mystery. In one 
study, seventeen participants were tested before and 
during inpatient psychotherapy at all three stages using 
psychiatric questionnaires, fMRI, and venipuncture. At 
similar time intervals, seventeen controllers were scanned. 
First, improvements in symptom severity, whole-brain 
and regional function, cortisol, serotonin, dopamine, 
brain-derived neurotrophic factor, and immunological 
parameters (IL-6, IL-10, TNF) were examined 
independently and aftercare. Second, stepwise linear 
simulation was used to discover relationships between 
the level variables. Since psychotherapy, the severity of 
OC, suicidal, and general symptoms was substantially 
decreased. The ACC activation, frontal areas, precuneus, 
and putamen had all diminished dramatically on a 
neuronal basis. On a neurochemical basis, no significant 
improvements were discovered. When the levels were 
associated, a critical model was discovered that explained 
the decrease in putamen neural activity by rising cortisol, 
IL-6, and dopamine concentrations.57
While some studies highlight the role of neurochemical 
agents in developing OCD symptoms, others do not 
consider their role to be significant. However, according 
to the available evidence, more extensive studies are 
needed to clarify the role of neurochemical agents and 
their use in the treatment of OCD.
Neurotherapeutics Approaches in OCD
The most well-accepted brain circuit model of psychological 
disorders is OCD, based on the concept of compulsions as 
habitual, almost unconscious behavior. Most of the habits 
are related to repetitive circuits called CSTC loops that 
link the cerebral cortex to the basal ganglia.58 CSTC loops 
will be hyperconnected or hyperactive and self-exciting 
in an uncontrolled positive feedback loop in the CSTC 
model. This increases the need to execute compulsions, 
which in turn strengthens/consolidates the practice of 
executing compulsions. Patients who use exposure and 
reaction avoidance treatment instead of practicing not 
to act on their compulsions will be able to intensify the 
chain.59 Obsessions or compulsions: who comes first, 
obsessions or compulsions?
The definition of CSTC circuit(s) has changed over 
time. Models have been based on an indirect in contrast 
to a direct pathway, with OCD being a misalignment of 
their relative drive. Although primary models assumed 
multiple parallel CSTC loops, and each loop was 
connected to different sides of basal ganglia and cortex, the 
advanced models have shown cascade spiral connections 
across the CSTC loops. However, according to all model 
variants, CSTC models should be hyperconnected and 
hyperactive in OCD.32 Human and animal trials support 
the model of the CSTC structure. The dorsal ACC, OFC, 
and caudate nucleus, which are involved in these circuits, 
are abnormally active in individuals with OCD at rest 
and with symptom arousal. This hyperactivity decreases 
with behavioral and pharmacological care.60 More 
recent research has applied this to physical connectivity 
as measured by fMRI and has discovered anomalies 
in various connections within the CSTC circuits once 
again.61 Executive function activities that specifically 
rely on these circuits indicate anomalies in patients with 
OCD.62
At last, SAPAP3, a crucial glutamate gene for CSTC loop 
production, has been knocked out in mice.63 Such mice 
have irregular cortico-striatal synaptic properties as well as 
abnormal (compulsive) grooming. Grooming ceases until 
the CSTC abnormality is reversed; pathological grooming 
occurs when nongenetic factors cause it. Although the 
mice model of compulsive grooming is a straightforward 
model for humans OCD, in general, its result supports the 
notion that CSTC defects play a critical role in OCD.64
The current neurocircuit theory has affected 
neurotherapeutic methods, such as efforts to treat OCD 
by intervening specifically with the function of the 
CSTC loop. Ablative surgeries and brain stimulation 
are included, with the latter categorized as invasive 
(deep brain stimulation) and non-invasive (transcranial 
magnetic stimulation). Subcaudate tractotomy, anterior 
capsulotomy, limbic leucotomy, and anterior cingulotomy 
are some of the surgical options. Both are backed by 
free-label data, which show response rates in the 36-75% 
(defined as a 36% or tremendous increase on the YBOCS) 
and overall favorable adverse effect profiles in terms of 
mortality or long-term morbidity.65 The value of response 
rate varies more between trials of the same protocol than 
between procedures. Capsulotomy, unlike the others, has 
been transformed into a gamma knife surgical technique, 
allowing for a simple sham-controlled experiment.66 
Although the trial’s primary analysis did not achieve 
statistical significance, long-term follow-up revealed 
improvements similar to open capsulotomy.
With the chance of adapting stimulation dose in 
response to patient improvement, brain stimulation 
extends the circuit-disrupting positions of the lesions. 
One of the most important measures is magnetic 
stimulation of the transcranial area, which quickly leads 
to depressive symptoms in patients.67 The left dorsolateral 
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prefrontal cortex target, which is used to treat depression, 
has little effect on OCD. The targeting supplementary 
motor area, which is more nearly connected to the 
c CSTC loops, caused modest positive effects in two 
experiments, including a meta-analysis study and two 
sham-controlled transcranial magnetic stimulations.68 
The supplementary motor area, while it is sometimes 
deemed experimental by insurers, transcranial magnetic 
stimulation can be recommended as an alternative to ERP 
therapy and evidence-based medicine.69 Stimulation of 
the brain deeply in the clinical challenge, the treatment 
chosen by the patient, is a more invasive procedure in 
which electrodes are implanted directly into the CSTC 
loop systems to provide sustained high-frequency 
stimulation. Some trials in Europe indicated that limbic 
regions in the subthalamic nucleus are an effective DBS 
site. Nevertheless, the ventral internal capsule is more 
interesting for most of the research teams.70
The DBS site, a white matter center with Many CSTC 
loops, has randomized and free-label clinical trial results 
to back up its effectiveness in OCD, with response rates 
ranging from 33-75%.71,72 An internal capsule of the ventral 
striatum based on those results, the US FDA approved 
DBS for OCD under a Humanitarian Device Exemption. 
DBS has many advantages over ablative treatments, 
including the fact that it is reversible and flexible. It 
enables tests of the brain with and without stimuli, 
confirming that DBS alters the function of various CSTC 
systems.72,73 On the other hand, those same properties 
cause patients to rebound as a result of system failures and 
possible stimulus overdoses, resulting in hypomania.74,75 
Closed-loop systems that self-adjust stimulus in response 
to CSTC loop operation could fix these issues, but they 
are still a work in progress.74,76 Both genetic and circuit 
research have traditionally viewed OCD as a discrete 
condition, a significant caveat. Many phenotypic subtypes 
of OCD have been identified by psychological factor 
studies, each with its biology; the same can be said for the 
occurrence or lack of comorbid tics. Experimental and 
clinical psychology are driving to a dimensional definition 
of disease, identifying patients’ impairments in particular 
areas of functioning, as previously stated. Since multiple 
CSTC loops are thought to lead to various aspects of the 
condition, OCD may be more amenable to the definition. 
If an accurate, quantifiable dimensional structure can be 
established, OCD neurotherapeutics’ targeting can be 
improved.76
Conclusion
For the past 30 years, progress in discovering the 
molecular, neurological, and developmental OCD 
underpinnings has surpassed that of any other medical 
condition. We anticipate that many core fields of OCD 
science will experience rapid growth and advancement 
in the future. First, because of the significant phenotypic 
variability in the diagnosis of OCD, further research into 
the biological discrepancies between subtypes of OCD 
symptoms should be conducted using deep phenotyping, 
a Research Domain Criteria (RDoC) methodology, and 
sophisticated neuroimaging techniques. In the next step, 
given the increasing body of evidence that glutamatergic 
dysfunction plays a role in OCD, new glutamate-
modulating therapies in OCD are warranted. Then, 
considering the proof of extinction learning deficits in 
OCD, more research into alternative pharmacologic, 
neuro-modulatory, or behavioral interventions to 
supplement ERP therapy should be prioritized. Moreover, 
there is much need for the development and refinement of 
neurotherapeutic/neurostimulation treatments for OCD. 
Finally, progress in these fields holds promise for medical 
approaches that can be administered neuro-scientifically 
for patients with OCD on an individualized basis using 
a personalized medicine approach to improve outcomes.
While a neurocircuit-based taxonomy for OCD is still in 
its beginnings, information gained over the last few decades 
about various neurocognitive functions related to OCD 
and their underlying neural pathways may offer insights 
into possible disease mechanisms and novel neurocircuit-
based treatment goals. Given that the standard medical 
method to identify psychiatric illness based on clusters of 
symptoms fails to show consistent and accurate circuitry 
defects across persons diagnosed with the same condition, 
medications that target particular circuits allow for 
treating their underlying symptomatology rather than 
the disorder as a whole. If specific changes in circuit 
regulating functions such as anxiety, subjective sensory 
perceptions, repetitive habits, reaction inhibition, reward, 
and executive function identify specific clinical profiles 
of OCD, treatments addressing those circuits and clinical 
profiles may be created. We hypothesize that effective 
management of OCD would necessitate treating different 
circuits, depending on the clinical profile, since OCD 
phenotypes include conflicting circuits. Given that some 
of these clinical profiles are used in other conditions (for 
example, sensory phenomena in tic disorders), specific 
circuit-based therapy methods may be used to address 
these clinical profiles through diseases rather than inside 
a particular categorical diagnosis until they are well 
defined.
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